Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Rare Opportunity? FDA Orphan Products Head Makes The Case For More Big Pharma Investment In Rare Diseases

Executive Summary

"Over the last 26 years, large pharmaceutical companies have missed an incredible opportunity," says Tim Coté, head of the Food & Drug Administration's Office of Orphan Product Development

You may also be interested in...



Rare Disease Drugs Need Faster Development Track, Sen. Brownback Tells FDA

Sen. Sam Brownback, R-Kansas, told FDA it should establish a second track for the development and approval of drugs for rare and neglected diseases

Rare Disease Drugs Need Faster Development Track, Sen. Brownback Tells FDA

Sen. Sam Brownback, R-Kansas, told FDA it should establish a second track for the development and approval of drugs for rare and neglected diseases

Pfizer Thinks Small: Partnership With Protalix On Gaucher Drug Eyes Cheaper Plant-Based Production

Pfizer's licensing deal with Protalix for global rights to the enzyme replacement therapy taliglucerase for the treatment of Gaucher disease, announced Dec. 1, signals the drug giant's interest in the orphan drug space. It also plays into the company's biosimilar strategy, given that taliglucerase will likely be positioned as a lower-cost alternative to Genzyme's Cerezyme (imiglucerase)

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051725

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel